In Italy, an essential drug for people suffering from pancreatic diseases has become unobtainable. The medicine (Creon or Creonipe), unlike almost all medicines, has no analogues that can replace it on the Italian market.
The shortage has been going on for several months, but reports from patients have increased in recent weeks. The situation is independent of the regulatory activities of Aifa, which has long provided patients and healthcare workers with adequate information, says Gabriele Capurso, general secretary of the European Pancreatic Club.